Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

FIVE at FIVE: Inflation reaches 40-year high, Darktrace executive in Britain’s biggest fraud and gold fund doubles

Here’s Proactive’s round-up of the top financial stories of the day, with helpful links taking you directly to the news

1. Inflation jumps to 9% - highest level since 1982

UK consumer price inflation hit 9% in April, which is the highest since current records began, according to new data from the Office for National Statistics, up from 7.0% in March.

Read more

2. Darktrace senior executive investigated for involvement in Britain’s largest ever fraud

The mid-cap company’s chief strategy officer Nicole Eagan was investigated by the US Department of Justice for her role in the £8.9bn (US$11bn) sale of software business Autonomy in 2011.

Read more

3. Royal Mint Gold ETF more than doubles in five months

Starting the year at US$278mln by April 29, the exchange-traded product's assets topped US$600mln, representing year-to-date growth of 117.6% and the highest assets under management since its launch in 2020.

Read more

4. FTSE topples on inflation figures

London's blue-chip index fell 1.1% to 7,438, ending three days of gains, as UK inflation data once again offered "a reminder of the struggles that lie ahead," commented Craig Erlam, a senior market analyst at OANDA.

Read more

5. Open Orphan lands £7.3mln influenza challenge study

Under the terms of the deal, the company researchers will carry out a double-blind, placebo-controlled assessment of the drug, which means one cohort will receive the active treatment, while the other half will be administered a substance with no medicinal value.

Read more

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK